Roche
NEWS
The decision to carry on came after dosing for the Phase III GENERATION HD1 trial was halted following an overall risk/benefit assessment.
The company’s vision for the next few years includes annual revenue of $5 billion by 2025 and the approval of at least five novel products by the end of the decade.
The Centers for Medicare and Medicaid Services indicated it would cover the cost of these drugs and any necessary scans — but only “if they are enrolled in qualifying clinical trials.”
Roche’s investment is aimed at supporting the development of Freenome’s colorectal cancer detection technology.
U.K.-based Clarivate Plc has identified seven late-stage assets or recently-approved drugs that could hit the billion-dollar per year mark within five years.
Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.
Going through the most newsworthy stories of the year, BioSpace found trends more than one big story, topics that just kept rising again and again. Here’s a look.
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.
JOBS
IN THE PRESS